Latest filing published 17 Sept 2024 for Biomarin Pharmaceutical INC, €19k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Henry J. Fuchs (board member) discloses dealings in 5 companies, chiefly Biomarin Pharmaceutical Inc, Onyx Pharmaceuticals Inc and Intrabiotics Pharmaceuticals Inc /DE. The record holds 396 filings, for trades running from 15 May 2006 to 13 September 2024.
No open-market purchase appears, only 173 sales worth €65.5M. Other entries cover 119 share grants and 100 option exercises. In 2024 alone, the filings show no purchases and 1 sale.
The latest filing, published on 17 September 2024, reports a share grant of €927k in Biomarin Pharmaceutical Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations